SPARCL1 and metabolic dysfunction-associated steatohepatitis: Notably, the SPARCL1-ALT-AST model demonstrates improved accuracy compared to the ALT-AST model in identifying patients with MASH, suggesting its potential as a noninvasive diagnostic marker (Liu et al., 2021).